Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 717
- Registration Number
- NCT06332274
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06331845
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 240
- Registration Number
- NCT06323382
- Locations
- 🇨🇳
Chinese PLA hospital, Beijing, Beijing, China
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 375
- Registration Number
- NCT06312982
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Friendship Hospital, Beijing, Beijing, China
Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Qiu Guoqin
- Target Recruit Count
- 30
- Registration Number
- NCT06303583
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- First Affiliated Hospital Bengbu Medical College
- Target Recruit Count
- 30
- Registration Number
- NCT06253598
Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC
- Conditions
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-02-02
- Target Recruit Count
- 40
- Registration Number
- NCT06238167
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 28
- Registration Number
- NCT06239532
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Xiang Lu
- Target Recruit Count
- 30
- Registration Number
- NCT06235918
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
- Conditions
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-01-31
- Target Recruit Count
- 30
- Registration Number
- NCT06233981
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciecnces and Peking Union Medical College, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.